U.S. CLIA Endocrine Testing Market (2026 - 2033) Size, Share & Trends Analysis Report By Product (Kits & Reagents, Instruments), By Testing Type, By Clinical Setting (OBGYN Office, Fertility / IVF Clinics), And Segment Forecasts

Table of Contents

Chapter 1. U.S. CLIA Endocrine Testing Market: Methodology and Scope
                    1.1. Market Segmentation and Scope
                        1.1.1. Segment Definitions
                            1.1.1.1. Product Method
                            1.1.1.2. Testing Type Segment
                            1.1.1.3. Clinical Settings Segment
                    1.2. Regional Scope
                    1.3. Estimates and Forecast Timeline
                    1.4. Objectives
                        1.4.1. Objective - 1
                        1.4.2. Objective - 2
                        1.4.3. Objective - 3
                    1.5. Research Methodology
                    1.6. Information Procurement
                        1.6.1. Purchased Database
                        1.6.2. GVR’s Internal Database
                        1.6.3. Secondary Sources
                        1.6.4. Primary Research
                    1.7. Information or Data Analysis
                        1.7.1. Data Analysis Models
                    1.8. Market Formulation & Validation
                    1.9. Model Details
                        1.9.1. Commodity Flow Analysis
                    1.10. List of Secondary Sources
                    1.11. List of Abbreviations
Chapter 2. U.S. CLIA Endocrine Testing Market: Executive Summary
                    2.1. Market Snapshot
                    2.2. Product Snapshot
                    2.3. Testing Type Snapshot
                    2.4. Clinical Settings Snapshot
                    2.5. Competitive Landscape Snapshot
Chapter 3. U.S. CLIA Endocrine Testing Market Variables, Trends, & Scope
                    3.1. Market Segmentation and Scope
                    3.2. Market Lineage Outlook
                        3.2.1. Parent Market Outlook
                        3.2.2. Related/Ancillary Market Outlook
                    3.3. Market Dynamics
                    3.4. Market Drivers Analysis
                        3.4.1. Increasing prevalence of chronic and hormonal disorders
                        3.4.2. Need for high sensitivity and analytical accuracy in hormone detection.
                        3.4.3. Advancements in automated CLIA platforms
                        3.4.4. Regulatory compliance under the clinical laboratory improvement amendments
                    3.5. Market Restraint Analysis
                        3.5.1. High cost of advanced CLIA platforms and testing infrastructure
                        3.5.2. Stringent regulatory and compliance requirements
                    3.6. Porter’s Five Forces Analysis
                    3.7. PESTLE Analysis
                    3.8. Pipeline Analysis
Chapter 4. U.S. CLIA Endocrine Testing Market: Product Estimates & Trend Analysis
                    4.1. U.S. CLIA Endocrine Testing Market: Product Dashboard
                    4.2. U.S. CLIA Endocrine Testing Market: Product Movement Analysis
                    4.3. U.S. CLIA Endocrine Testing Market by therapy, Revenue
                    4.4. Kits & Reagents
                        4.4.1. Kits & Reagents market estimates and forecasts 2021 to 2033 (USD Million)
                    4.5. Instruments
                        4.5.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. CLIA Endocrine Testing Market, By Testing Type, 2021 - 2033 Value (USD Million), Volume (Number of tests)
                    5.1. Thyroid Testing market estimates and forecasts 2021 to 2033 (USD Million)
                        5.1.1. TSH market estimates and forecasts 2021 to 2033 (USD Million)
                        5.1.2. Free T4 (fT4) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.1.3. T4 (Total) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.1.4. Free T3 (FT3) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.1.5. T3 (Total) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.1.6. Anti-TPO market estimates and forecasts 2021 to 2033 (USD Million)
                        5.1.7. Anti-Tg market estimates and forecasts 2021 to 2033 (USD Million)
                        5.1.8. Thyroglobulin (Tg) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.1.9. T3 Resin Uptake market estimates and forecasts 2021 to 2033 (USD Million)
                    5.2. Hormone Testing market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.1. FSH market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.2. hCG market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.3. Testosterone market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.4. Progesterone market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.5. Prolactin market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.6. Estradiol E2 market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.7. Luteinizing Hormone (LH) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.8. Sex Hormone-Binding Globulin (SHBG) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.9. DHEA-S (dehydroepiandrosterone sulfate) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.10. Human growth hormone (HGH) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.2.11. Anti-Müllerian Hormone (AMH) market estimates and forecasts 2021 to 2033 (USD Million)
                    5.3. Bone Health market estimates and forecasts 2021 to 2033 (USD Million)
                        5.3.1. Vitamin D market estimates and forecasts 2021 to 2033 (USD Million)
                        5.3.2. Parathyroid hormone (PTH) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.3.3. Serum CTX (Carboxy-terminal collagen crosslinks) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.3.4. NTx (N-telopeptide) market estimates and forecasts 2021 to 2033 (USD Million)
                        5.3.5. Osteocalcin market estimates and forecasts 2021 to 2033 (USD Million)
                        5.3.6. Alkaline phosphatase (ALP) market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. CLIA Endocrine Testing Market, Clinical Setting by Testing Type, 2021 - 2033 Value (USD Million), Volume (Number of tests)
                    6.1. U.S. CLIA Endocrine Testing Market: Testing Type, Value (USD Million), Volume (Number of tests) Dashboard
                    6.2. U.S. CLIA Endocrine Testing Market: Testing Type, Value (USD Million), Volume (Number of tests) Movement Analysis
                    6.3. U.S. CLIA Endocrine Testing Market by Testing Type, Value (USD Million), Volume (Number of tests)
                    6.4. OBGYN office
                        6.4.1. OBGYN office market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
                    6.5. Physician office labs (POLs)
                    6.6. Physician office labs (POLs) market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
                    6.7. Hospital Labs Small (<100 beds)
                        6.7.1. Hospital Labs Small (<100 beds) market estimates and forecasts 2021 to 2033 (USD Million)(Number of tests)
                    6.8. Hospital Labs Medium (100-500 beds)
                        6.8.1. Hospital Labs Medium (100-500 beds) market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
                    6.9. Hospital Labs Large (>500 beds)
                        6.9.1. Hospital Labs Large (>500 beds) market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
Chapter 7. Competitive Landscape
                    7.1. Recent Developments & Impact Analysis, By Key Market Participants
                    7.2. Company/Competition Categorization
                    7.3. Vendor Landscape
                    7.4. List of key distributors and channel partners
                    7.5. Key customers
                    7.6. Key company market share analysis, 2025
                        7.6.1. F. Hoffmann-La Roche Ltd
                            7.6.1.1. Company overview
                            7.6.1.2. Financial performance
                            7.6.1.3. Product benchmarking
                            7.6.1.4. Strategic initiatives
                        7.6.2. Abbott
                            7.6.2.1. Company overview
                            7.6.2.2. Financial performance
                            7.6.2.3. Product benchmarking
                            7.6.2.4. Strategic initiatives
                        7.6.3. Siemens Medical Solutions USA, Inc.
                            7.6.3.1. Company overview
                            7.6.3.2. Financial performance
                            7.6.3.3. Product benchmarking
                            7.6.3.4. Strategic initiatives
                        7.6.4. QuidelOrtho Corporation
                            7.6.4.1. Company overview
                            7.6.4.2. Financial performance
                            7.6.4.3. Product benchmarking
                            7.6.4.4. Strategic initiatives
                        7.6.5. DiaSorin S.p.A.
                            7.6.5.1. Company overview
                            7.6.5.2. Financial performance
                            7.6.5.3. Product benchmarking
                            7.6.5.4. Strategic initiatives
                        7.6.6. Beckman Coulter, Inc.
                            7.6.6.1. Company overview
                            7.6.6.2. Financial performance
                            7.6.6.3. Product benchmarking
                            7.6.6.4. Strategic initiatives
                        7.6.7. Quest Diagnostics Incorporated
                            7.6.7.1. Company overview
                            7.6.7.2. Financial performance
                            7.6.7.3. Product benchmarking
                            7.6.7.4. Strategic initiatives
                        7.6.8. Labcorp
                            7.6.8.1. Company overview
                            7.6.8.2. Financial performance
                            7.6.8.3. Product benchmarking
                            7.6.8.4. Strategic initiatives
                        7.6.9. Thermo Fisher Scientific Inc.
                            7.6.9.1. Company overview
                            7.6.9.2. Financial performance
                            7.6.9.3. Product benchmarking
                            7.6.9.4. Strategic initiatives
                        7.6.10. Bio-Rad Laboratories, Inc.
                            7.6.10.1. Company overview
                            7.6.10.2. Financial performance
                            7.6.10.3. Product benchmarking
                            7.6.10.4. Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. CLIA Endocrine Testing Market, By Product, 2021 - 2033 (USD Million)
Table 4 U.S. CLIA Endocrine Testing Market, By Testing Type, Volume (Number of tests), 2021 - 2033 (USD Million)
Table 5 U.S. CLIA Endocrine Testing Market, By Clinical Setting, Volume (Number of tests), 2021 - 2033 (USD Million)

List of Figures

Fig. 1 U.S. CLIA endocrine testing market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment.
Fig. 8 Market formulation & validation
Fig. 9 U.S. CLIA endocrine testing market snapshot
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook.
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. CLIA endocrine testing market: Product movement analysis
Fig. 14 U.S. CLIA endocrine testing market: Product outlook and key takeaways
Fig. 15 Kits & reagents market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 16 Instruments market estimates and forecast, 2021 - 2033 (USD Million)
Fig. 17 U.S. CLIA endocrine testing market: clinical setting, volume (number of tests) movement analysis
Fig. 18 U.S. CLIA endocrine testing market: clinical setting, volume (number of tests) outlook and key takeaways
Fig. 19 Parenteral market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 20 OBGYN office market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 21 Fertility / IVF clinics market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 22 Physician office labs (POLs) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 23 Hospital labs medium (100-500 beds) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 24 Hospital Labs Large (>500 beds) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 25 Others market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 26 U.S. CLIA endocrine testing market: testing type, volume (number of tests) movement analysis
Fig. 27 U.S. CLIA endocrine testing market: testing type, volume (number of tests) outlook and key takeaways
Fig. 28 Thyroid Testing market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 29 TSH market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 30 Free T4 (fT4) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 31 T4 (Total) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 32 Free T3 (FT3) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 33 T3 (Total) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 34 Anti-TPO market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 35 Anti-Tg market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 36 Thyroglobulin (Tg) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 37 T3 Resin Uptake market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 38 Hormone Testing market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 39 FSH market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 40 Hcg market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 41 Testosterone market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 42 Progesterone market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 43 Prolactin market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 44 Estradiol E2 market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 45 Luteinizing Hormone (LH) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 46 Sex Hormone-Binding Globulin (SHBG) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 47 DHEA-S (dehydroepiandrosterone sulfate) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 48 Human growth hormone (HGH) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 49 Anti-Müllerian Hormone (AMH) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 50 Bone Health market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 51 Vitamin D market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 52 Parathyroid hormone (PTH) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 53 Serum CTX (Carboxy-terminal collagen crosslinks) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 54 Market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 55 NTx (N-telopeptide) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 56 Osteocalcin market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 57 Alkaline phosphatase (ALP) market estimates and forecast, 2021 - 2033 (USD Million) (Number of tests)
Fig. 58 U.S. CLIA endocrine testing market: Product movement analysis
Fig. 59 U.S. CLIA endocrine testing market: Product outlook and key takeaways
Fig. 60 U.S. CLIA endocrine testing market: Clinical settings movement analysis
Fig. 61 U.S. CLIA endocrine testing market: Clinical settings outlook and key takeaways
Fig. 62 U.S. CLIA endocrine testing market: Testing type movement analysis
Fig. 63 U.S. CLIA endocrine testing market: Testing type outlook and key takeaways
Fig. 64 Market share of key market players- U.S. CLIA endocrine testing market